October 10th 2025
A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.
September 22nd 2025
Aprepitant Warrants More Study for CINV in Patients on FOLFOX for CRC
November 16th 2017Aprepitant plus palonosetron and dexamethasone showed early promise for preventing chemotherapy-induced nausea and vomiting among patients with colorectal cancer who are undergoing FOLFOX chemotherapy, according to results of a small pilot study.
High HER3 Expression in Advanced CRC Related to Anti-EGFR Activity
October 30th 2017HER3 messenger RNA expression may serve as a biomarker for patients with RAS wild type colorectal cancer who will benefit from treatment with the anti-EGFR therapy panitumumab, according to the results of a new study.
Nonoperative Management of Rectal Cancer: A Modern Perspective
In this article, we provide a summary of nonoperative management of locally advanced rectal cancer in the modern era. Our focus is on technical details of tumor response and patient assessment after chemoradiotherapy, as well as a review of existing clinical data.
Adjuvant Chemo Improved Survival in Gastroesophageal Cancer
October 2nd 2017Treatment with adjuvant chemotherapy improved the overall survival of locally advanced gastroesophageal adenocarcinoma in patients treated with preoperative chemoradiotherapy and resection, according to the results of an analysis of the National Cancer Database.
MVA-5T4, Low-Dose Cyclophosphamide in mCRC Showed Survival Benefit
September 21st 2017A combination of modified vaccinia Ankara-5T4 (MVA-5T4) and low-dose cyclophosphamide, or either treatment given alone, demonstrated significant survival benefit in a small group of patients with metastatic colorectal cancer compared with no treatment.
Updated Results Show Continued Pembrolizumab Activity in Gastric Cancer
September 11th 2017Updated results from the KEYNOTE 059 phase II trial showed that pembrolizumab alone or in combination with chemotherapy has promising antitumor activity for patients with advanced gastric or gastroesophageal junction cancer.
Colorectal Cancer Mortality Rates Increasing in Younger White Patients
August 17th 2017Mortality from colorectal cancer has decreased since 1970 in young black patients aged 20 to 54, but has increased in white patients since 1995 in those aged 30 to 39 years and since 2005 in those aged 40 to 54 years after decades of decreasing.
Novel Agent S-1 Has Similar Efficacy to 5-FU in Certain Gastric Cancers
August 10th 2017Results of a phase III trial suggest that the combination of the contemporary oral fluoropyrimidine S-1 and cisplatin offers similar efficacy to 5-flourouracil and cisplatin in patients with chemotherapy-naive diffuse type adenocarcinoma of the gastroesophageal junction or stomach.
Current Pancreatic Cancer Guidelines Miss Targetable Mutations
August 10th 2017Germline mutations in pancreatic cancer susceptibility genes were commonly identified in a group of patients with pancreatic cancer who did not report a significant family history of cancer, according to the results of a single-center study.
Parts of Mediterranean Diet Linked With Reduced Colon Polyp Risk
July 11th 2017Adherence to a Mediterranean diet is negatively associated with advanced colorectal polyps, and the specific portions of the diet that appear to have the most influence include high intake of fish and fruit and low intake of soft drinks.